GSK-4418959 (IDE275): A Comprehensive Analysis of a Novel, Reversible WRN Inhibitor Poised to Redefine Treatment for MSI-High Solid Tumors

Section 1: Executive Summary

GSK-4418959, also identified as IDE275, is an orally bioavailable, small-molecule inhibitor emerging from a strategic collaboration between GlaxoSmithKline (GSK) and IDEAYA Biosciences. This investigational agent is positioned as a potential first-in-class and best-in-class therapeutic targeting Werner syndrome helicase (WRN), a pivotal enzyme in the DNA damage response (DDR) pathway. The development of GSK-4418959 embodies a precision oncology strategy founded on the principle of synthetic lethality, aiming to exploit a specific genetic vulnerability present in a well-defined subset of solid tumors.

The drug's therapeutic focus is on patients with solid tumors characterized by high microsatellite instability (MSI-H) or deficient DNA mismatch repair (dMMR). In these cancer cells, the loss of the primary DNA repair function of the MMR system creates a critical dependency on the WRN helicase to resolve complex DNA structures and maintain genomic integrity during replication. By inhibiting the helicase activity of WRN, GSK-4418959 is designed to induce an overwhelming accumulation of DNA damage, leading to catastrophic replication stress and the selective death of cancer cells, while sparing healthy, microsatellite-stable (MSS) cells.

A key differentiator for GSK-4418959 lies in its unique mechanism of action. Unlike first-generation covalent WRN inhibitors, it employs a non-covalent, reversible binding mode to a distinct allosteric site on the WRN protein.[1] This novel interaction has translated into compelling preclinical evidence, where the compound has demonstrated potent, single-agent efficacy, inducing tumor regressions in patient-derived models of MSI-H colorectal, endometrial, and gastric cancers. Critically, GSK-4418959 has maintained its anti-tumor activity in preclinical models engineered for acquired resistance to other clinical-stage covalent WRN inhibitors, a finding that strongly supports its potential best-in-class profile.[1]

The compound has advanced into clinical development with the initiation of the SYLVER trial (NCT06710847), a first-in-human, Phase 1/2 study. The trial is strategically designed with multiple parts to efficiently assess the safety and efficacy of GSK-4418959 both as a monotherapy and in combination with a PD-1 inhibitor.[4] A core focus of the study is on heavily pre-treated patients, including those whose cancers have progressed on or after standard-of-care immunotherapy, directly addressing a significant and growing unmet medical need.

The competitive landscape for WRN inhibitors is dynamic and has been recently reshaped by the discontinuation of the clinical program for Roche's covalent inhibitor, RO7589831, which was once the frontrunner. This development has intensified the focus on the differentiated profiles of non-covalent agents like GSK-4418959. Its potential to overcome resistance, combined with the robust developmental and financial backing of the GSK-IDEAYA partnership, positions it as a leading contender in this novel therapeutic class. The initial clinical data from the SYLVER trial, anticipated in 2025, represents a pivotal catalyst that will be closely watched by the oncology community and will likely shape the future trajectory of the entire WRN inhibitor field.

Section 2: The Scientific Foundation: Targeting WRN in MSI-High Cancers

The therapeutic strategy underpinning GSK-4418959 is rooted in a deep understanding of cancer genetics and the concept of synthetic lethality. This approach targets a specific vulnerability that arises in a subset of tumors with a defined genetic background, offering the potential for highly selective and potent anti-cancer activity. Central to this strategy are the Werner syndrome helicase (WRN) protein and its essential role in tumors with high microsatellite instability (MSI-H).

2.1 The Role of Werner Syndrome Helicase (WRN) in Genomic Stability

Werner syndrome helicase, or WRN, is a multifunctional enzyme and a member of the highly conserved RecQ family of DNA helicases.[1] These proteins function as crucial "caretakers of the genome," playing indispensable roles in a variety of DNA metabolic processes, including DNA replication, repair, and recombination.[1] WRN's primary function is to act as a molecular motor that unwinds complex and non-canonical DNA secondary structures. These structures, such as Holliday junctions, D-loops, forked duplexes, and G-quadruplexes, can form during DNA replication and, if left unresolved, can obstruct the replication machinery, leading to genomic instability.[1]

A distinguishing characteristic of WRN, which sets it apart from other human RecQ helicases, is its dual enzymatic functionality. The protein possesses both a 3’→5’ DNA helicase activity, which is responsible for unwinding DNA, and a 3’→5’ exonuclease activity, which can degrade DNA strands.[6] While both functions are important for its role in DNA maintenance, extensive research has demonstrated that the synthetic lethal dependency observed in MSI-H cancers is linked specifically and exclusively to its helicase function.[8]

The clinical importance of WRN is profoundly illustrated by Werner syndrome, a rare, autosomal recessive disorder caused by germline loss-of-function mutations in the WRN gene.[9] Individuals with this syndrome exhibit features of accelerated aging, including cataracts, type 2 diabetes, and osteoporosis, and have a markedly increased predisposition to various types of cancer.[9] This human genetic evidence provides a powerful validation of WRN's critical role in maintaining genomic integrity and preventing tumorigenesis.

2.2 The Synthetic Lethal Paradigm in MSI-High Tumors

The development of GSK-4418959 is predicated on the concept of synthetic lethality, a therapeutic principle that has gained significant traction in precision oncology. A synthetic lethal interaction occurs when the simultaneous loss of function of two distinct genes (or the inhibition of one protein in the context of a pre-existing genetic defect in another) results in cell death, whereas the loss of either one alone is compatible with cell viability.[10] This provides a therapeutic window to selectively kill cancer cells that harbor a specific genetic mutation while sparing normal cells that lack this alteration. The clinical success of PARP inhibitors in patients with

BRCA1/2-mutated cancers is the most prominent example of this approach.

The specific synthetic lethal relationship exploited by GSK-4418959 exists between the inhibition of WRN and a genetic feature known as high microsatellite instability (MSI-H). This feature arises from a deficient DNA mismatch repair (dMMR) system.[1] The MMR system is the cell's primary mechanism for correcting errors, such as base mismatches and small insertions or deletions, that occur during DNA replication. When MMR genes (e.g.,

MLH1, MSH2, MSH6, PMS2) are inactivated through mutation or epigenetic silencing, the cell loses its ability to perform this proofreading function. This leads to a hypermutator phenotype, where mutations accumulate at a rate up to 1,000 times higher than in normal cells.[12]

This hypermutability is particularly pronounced in microsatellites, which are short, repetitive sequences of DNA (e.g.,...TATATATA...). Due to their repetitive nature, these regions are highly prone to "slippage" by the DNA polymerase during replication, creating insertion-deletion loops that are normally corrected by the MMR system. In dMMR cells, these errors go uncorrected, leading to widespread changes in the length of microsatellites throughout the genome—the hallmark of MSI-H.[1]

A critical downstream consequence of this long-term genomic instability is the expansion of specific microsatellites, most notably TA-dinucleotide repeats.[1] These expanded TA-repeat sequences are inherently unstable and have a high propensity to form non-B DNA secondary structures, such as hairpins and cruciforms, which act as physical barriers to the DNA replication machinery.[8] This accumulation of problematic DNA structures throughout the genome is often referred to as a "genomic scar".[14]

In normal, microsatellite-stable (MSS) cells, which have a functional MMR system, these TA-repeat structures do not accumulate to the same degree, and WRN's function is largely redundant and dispensable. However, in MSI-H cancer cells, the constant formation of these replication-blocking structures creates a profound and critical dependency on WRN's helicase activity to resolve them and allow DNA replication to proceed.[1] This acquired dependency is the synthetic lethal vulnerability that WRN inhibitors are designed to exploit.

When a drug like GSK-4418959 inhibits WRN in an MSI-H cancer cell, the replication forks that encounter these TA-repeat structures become permanently stalled. This triggers a cascade of events where the stalled forks collapse and are converted into highly toxic, double-strand DNA breaks.[1] The sheer volume of these breaks overwhelms the cell's remaining repair capacity, leading to widespread genomic fragmentation, cell cycle arrest, and ultimately, apoptosis (programmed cell death).[16] Because healthy MSS cells are not dependent on WRN, they are largely unaffected by its inhibition, providing the basis for a highly selective, targeted cancer therapy.

2.3 WRN as a High-Value Precision Oncology Target

The identification of the WRN-MSI synthetic lethal interaction has positioned WRN as one of the most promising new targets in precision oncology. This designation is supported by several key factors. First, the dependency was independently validated in multiple large-scale, genome-wide CRISPR screens, which identified WRN as a top essential gene specifically in MSI-H cancer cell lines, irrespective of their tissue of origin.[3] This suggests that WRN inhibition has the potential to be a tumor-agnostic therapy, applicable to any solid tumor that exhibits the MSI-H biomarker. This is a highly attractive feature from both a clinical and commercial perspective, mirroring the successful tumor-agnostic approvals of immune checkpoint inhibitors for the same biomarker.

Second, the MSI-H biomarker is present in a clinically and commercially significant patient population across several of the most common cancer types. Reported prevalence rates for MSI-H are approximately 31% in endometrial cancer, 20% in colorectal cancer, and 19% in gastric cancer, with lower frequencies in other solid tumors.[10] This defines a substantial addressable market for a successful WRN inhibitor.

The evidence strongly suggests that the direct driver of WRN dependency is the accumulation of a specific type of genomic lesion—expanded TA-dinucleotide repeats—which is a direct consequence of MMR deficiency. While MSI-H status serves as an excellent and clinically established surrogate biomarker for identifying patients likely to benefit, the underlying biology points to a more quantitative relationship. Preclinical studies have shown that the degree of sensitivity to WRN inhibition, including with GSK-4418959, correlates with the prevalence of TA-repeats in a given cell line.[8] This implies that the therapeutic window and depth of response may be governed by the quantitative burden of this "genomic scar." This opens the possibility of developing more refined, second-generation patient selection strategies beyond the current binary MSI-H/MSS classification. A quantitative biomarker based on TA-repeat load could potentially predict which MSI-H patients will derive the most profound benefit, explain variability in patient responses, and optimize the design of future clinical trials.

Section 3: GSK-4418959 (IDE275) - A Differentiated Molecular Profile

GSK-4418959 (IDE275) has been meticulously engineered to not only potently and selectively inhibit its target, WRN, but also to possess a distinct molecular profile that differentiates it from other inhibitors in development. This differentiation is centered on its novel mechanism of action, which was likely a deliberate strategic choice to address the anticipated clinical challenge of acquired resistance.

3.1 Chemical and Pharmacological Properties

GSK-4418959 is an orally bioavailable, selective small-molecule drug developed for the treatment of solid tumors.[5] Its discovery and development are the result of a collaborative effort between GSK and IDEAYA Biosciences. The compound is referred to by several synonyms in scientific literature and company communications, including GSK4418959, IDE275, and GSK959.[2] The chemical properties of the molecule are well-defined, providing a clear identity for this new chemical entity.

Table 1: GSK-4418959 (IDE275) Drug Profile Summary

Attribute	Description	Source(s)
Synonyms	GSK4418959, IDE275, GSK959	10
Drug Class	Small molecule, Antineoplastic	22
Target	Werner syndrome helicase (WRN)	1
Mechanism of Action	Allosteric, non-covalent, reversible WRN helicase inhibitor; ATP-competitive	2
Developers	GlaxoSmithKline (GSK), IDEAYA Biosciences	1
Chemical Formula	C31​H30​F4​N4​O5​S	23
Molecular Weight	646.66 g/mol	23
CAS Number	3064599-36-3	23
IUPAC Name	(1R,2R,6S)-2-((2-fluoro-4-(trifluoromethyl)phenyl)carbamoyl)-6-(4-((N,1,2-trimethyl-1H-benzo[d]imidazole)-5-sulfonamido)phenyl)cyclohexane-1-carboxylic acid	23

3.2 A Novel Mechanism of Action: Non-Covalent, Reversible Inhibition

The most significant differentiating feature of GSK-4418959 is its mechanism of action. It is a non-covalent, reversible, allosteric inhibitor of the WRN helicase.[1] This stands in contrast to first-generation WRN inhibitors, such as RO7589831, which bind covalently and irreversibly to their target.[1]

Based on X-ray crystallography studies, GSK-4418959 engages a unique, cryptic allosteric pocket within the helicase domain of the WRN protein.[1] This binding site is distinct from those used by other reported WRN inhibitors, and its engagement induces a specific inhibitory conformation in the protein.[3] By stabilizing this inactive state, GSK-4418959 functions as an

ATP-competitive inhibitor; it sterically hinders the binding of ATP to its catalytic site, thereby preventing the hydrolysis reaction that powers WRN's essential DNA unwinding activity.[3] This inhibition is highly selective for WRN, as the compound has shown no measurable activity against other members of the RecQ helicase family, such as BLM helicase, underscoring its precision.[3]

The selection of a non-covalent, reversible mechanism appears to be a highly intentional, second-generation drug design strategy. In oncology, targeted therapies that form a permanent covalent bond with their target protein can be highly potent but are also vulnerable to a specific mode of acquired resistance: mutations in the target protein at or near the covalent binding site (e.g., the cysteine residue C727 in WRN, which is targeted by some covalent inhibitors) can prevent the drug from binding, rendering it ineffective.[27] By designing GSK-4418959 to bind reversibly to a completely different allosteric site, the developers have created a molecule that is mechanistically poised to circumvent this anticipated resistance mechanism. This foresight is central to the drug's "best-in-class" potential and could provide a critical advantage in the clinical setting if on-target resistance mutations prove to be a common escape pathway for tumors treated with covalent WRN inhibitors.

3.3 Preclinical Evidence of Potency and Selectivity

The unique mechanism of GSK-4418959 has translated into a compelling preclinical data package that validates its potential. Across a wide range of preclinical models, the drug has been shown to effectively phenocopy the effects of genetic silencing of the WRN gene.[17] It has demonstrated potent, single-agent anti-tumor activity, inducing deep and durable tumor regressions in MSI-H models. These models include cell line-derived xenografts (CDX), more clinically relevant patient-derived xenografts (PDX), and three-dimensional patient-derived organoids (PDOs) from tumors of diverse histological origins, including colorectal, endometrial, and gastric cancers.[1]

The drug's activity is exquisitely selective for the target population. In head-to-head studies, GSK-4418959 elicited strong anti-proliferative effects and cell death in MSI-H cancer models but had no measurable impact on the viability of analogous MSS models.[3] This provides robust preclinical validation of the synthetic lethal concept and suggests a wide therapeutic window, as healthy tissues are MSS and should be spared.

Perhaps the most critical preclinical finding is the ability of GSK-4418959 to overcome acquired resistance to other WRN inhibitors. In tumor models that were first treated with covalent inhibitors like RO7589831 or HRO761 until they developed resistance and resumed growth, subsequent treatment with GSK-4418959 was still able to induce tumor regression.[1] This powerful demonstration supports the hypothesis that its unique binding mode allows it to remain effective even when cancer cells have evolved to evade other WRN-targeting agents, solidifying its best-in-class potential.

The biological effects of the drug have been confirmed with pharmacodynamic markers. Treatment with GSK-4418959 leads to a dose- and time-dependent induction of DNA damage markers, such as phosphorylated H2AX (γH2AX) and phosphorylated KAP1 (pKAP1), specifically within MSI-H cells and tumors.[21] These markers, which can be measured in tumor biopsies via techniques like immunohistochemistry (IHC), serve as direct evidence of the drug's on-target mechanism and are being integrated into the clinical program to monitor biological response and guide dose selection.[21]

Section 4: Clinical Development Program - The SYLVER Trial

Following a robust preclinical validation program and clearance of its Investigational New Drug (IND) application in October 2024, GSK-4418959 has advanced into human clinical trials.[10] The cornerstone of its clinical development is the SYLVER study, a strategically designed Phase 1/2 trial aimed at efficiently evaluating the drug's safety, pharmacokinetics, and preliminary efficacy in its target patient population.

4.1 Overview of NCT06710847 (SYLVER)

The SYLVER trial is a first-in-human, open-label, multicenter study with the full title, "A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors".[4] The trial officially opened for recruitment on December 9, 2024, and is sponsored by GSK in collaboration with IDEAYA Biosciences.[1] It has a global footprint, with a planned enrollment of approximately 133 patients across sites in the United States, Australia, Japan, South Korea, and several European countries.[5] The estimated primary completion date for the study is June 16, 2028.[30]

Table 2: SYLVER (NCT06710847) Clinical Trial Design

Parameter	Details
Trial Identifier	NCT06710847
Title	SYLVER: A Study of GSK4418959 in Participants With dMMR/MSI-H Solid Tumors
Phase	1/2
Study Design	Open-label, multicenter, non-randomized, 3-part dose escalation and expansion study
Target Population	Adult patients (≥18 years) with advanced (unresectable/metastatic) dMMR/MSI-H solid tumors
Part 1: Monotherapy Dose Escalation	Intervention: GSK4418959 MonotherapyPrimary Endpoint: Incidence of Dose-Limiting Toxicities (DLTs) to determine the Recommended Phase 2 Dose (RP2D)
Part 2: Monotherapy Dose Expansion	Intervention: GSK4418959 Monotherapy at RP2D in CRC and EC cohortsPrimary Endpoint: Objective Response Rate (ORR) per RECIST 1.1
Part 3: Combination Dose Escalation	Intervention: GSK4418959 + PD-1 InhibitorPrimary Endpoint: Incidence of DLTs to determine the combination RP2D
Key Biomarkers	Patient Selection: dMMR/MSI-H statusPharmacodynamic: γH2AX, pKAP1, WRN Target Occupancy

4.2 Study Design and Objectives

The SYLVER trial employs a sophisticated, multi-part, sequential assignment design to maximize data generation from a single protocol.[4] This approach allows for the parallel investigation of monotherapy and combination therapy, accelerating the overall development timeline. The study is divided into three main parts:

• Part 1 (Monotherapy Dose Escalation): This initial part of the trial is designed to establish the safety and tolerability of GSK-4418959 as a single agent. Successive cohorts of patients receive escalating doses of the drug to identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D). The primary endpoint for this part is the incidence of dose-limiting toxicities (DLTs), which are specific, severe adverse events that occur within the first 21 days of treatment.[4]
• Part 2 (Monotherapy Dose Expansion): Once the RP2D is determined in Part 1, the trial will expand to enroll larger cohorts of patients with specific tumor types—namely, advanced colorectal cancer (CRC) and endometrial cancer (EC)—to be treated at that dose. The primary objective of this part is to assess the preliminary anti-tumor activity of GSK-4418959 monotherapy. The primary endpoint is the Objective Response Rate (ORR), as measured by tumor shrinkage according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).[4]
• Part 3 (Combination Dose Escalation): Running in parallel, this part of the study will evaluate the safety and tolerability of GSK-4418959 when given in combination with a programmed cell death protein-1 (PD-1) inhibitor.[4] One source identifies the PD-1 inhibitor as dostarlimab, another GSK asset.[32] Similar to Part 1, this arm will use a dose-escalation design to determine the MTD and RP2D for the combination regimen, with DLTs as the primary endpoint.[5]

Secondary objectives across all parts of the trial are comprehensive and include assessments of the overall safety profile, pharmacokinetic parameters (such as maximum concentration, Cmax​, and time to maximum concentration, Tmax​), and additional efficacy endpoints for the expansion cohorts, such as progression-free survival (PFS) and duration of response (DOR).[5]

4.3 Patient Population and Biomarker Strategy

The SYLVER trial is a prime example of biomarker-driven clinical development. Patient eligibility is strictly defined by the molecular characteristics of their tumors to align with the drug's mechanism of action.

The core inclusion criterion for all participants is a histologically confirmed diagnosis of an advanced (unresectable, metastatic, or recurrent) solid tumor that has a known deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) status.[4] This status must be determined by a certified laboratory, ensuring that only patients with the specific genetic vulnerability targeted by the drug are enrolled.[5]

The trial design shrewdly targets the patient population with the highest unmet medical need. The standard of care for first-line metastatic MSI-H colorectal cancer is now immunotherapy with pembrolizumab, following the practice-changing results of the KEYNOTE-177 trial.[34] Similarly, dostarlimab has shown unprecedented activity in neoadjuvant MSI-H rectal cancer.[36] While these immunotherapies are highly effective for many, a significant subset of patients either do not respond (primary resistance) or their disease progresses after an initial response (acquired resistance). This ICI-experienced population has very limited effective treatment options.

The SYLVER trial directly addresses this gap. While the dose-escalation parts (1 and 3) enroll patients who have exhausted all standard therapies, the monotherapy expansion arm (Part 2) specifically enrolls patients with CRC or EC who have received between one and three prior lines of systemic therapy for their advanced disease, including at least one line of immune checkpoint inhibitor (ICI) therapy.[4] This design is not merely a standard first-in-human study but a highly strategic "fastest path to market" approach. Demonstrating clear efficacy in this well-defined, post-immunotherapy population would establish a crucial clinical niche for GSK-4418959 and could provide a basis for accelerated regulatory approval, without needing to initially challenge the entrenched immunotherapy standard of care in the first-line setting.

The trial also incorporates a robust translational biomarker plan. In addition to the dMMR/MSI-H selection biomarker, the study will collect tumor biopsies to measure pharmacodynamic (PD) biomarkers that confirm the drug is hitting its target and eliciting the expected biological response. Based on strong preclinical data, these include measuring the induction of DNA damage markers like γH2AX and pKAP1 and using a novel, highly specific mass spectrometry-based target occupancy assay to directly quantify the percentage of WRN protein that is bound by GSK-4418959 in tumor tissue.[21] These PD markers will be critical for understanding the dose-response relationship and confirming the drug's mechanism of action in patients.

4.4 Rationale for Combination Therapy with PD-1 Inhibitors

The inclusion of a combination arm with a PD-1 inhibitor in the SYLVER trial is based on a strong scientific rationale and a clear clinical strategy. There is a well-established biological synergy between drugs that induce DNA damage and immunotherapies that unleash the immune system against cancer.

Mechanistically, DDR inhibitors like GSK-4418959 function by causing extensive DNA damage and genomic instability within cancer cells.[38] This process can lead to the generation and release of tumor-specific neoantigens—mutated proteins that the immune system can recognize as foreign. By increasing the neoantigen load, WRN inhibition has the potential to make "cold" or immunologically quiet tumors more "hot," or visible to the immune system.[40] This enhanced immunogenicity can, in turn, make the tumors more susceptible to the action of immune checkpoint inhibitors like PD-1 blockers, which work by removing the "brakes" on cancer-fighting T cells.[1] The combination, therefore, aims to create a powerful, two-pronged attack: the WRN inhibitor directly damages and kills cancer cells while also flagging them for destruction by an immune system re-energized by the PD-1 inhibitor.

Clinically, this combination strategy is designed to address the limitations of current immunotherapy. For the significant number of MSI-H patients who are refractory to or relapse after PD-1 inhibitor monotherapy, adding a WRN inhibitor could overcome resistance and re-sensitize their tumors to immune attack.[1] For patients receiving treatment for the first time, the combination could potentially lead to higher response rates and more durable responses than either agent alone. This combination approach is a consensus strategy within the field, with nearly all clinical-stage WRN inhibitor programs, including those for RO7589831 and HRO761, also exploring combinations with PD-1 inhibitors and/or chemotherapy.[1]

Section 5: Competitive and Strategic Landscape

GSK-4418959 is entering a nascent but highly competitive field. The validation of WRN as a synthetic lethal target for MSI-H cancers has spurred a race among several biotechnology and pharmaceutical companies to develop and commercialize the first WRN inhibitor. The strategic positioning of GSK-4418959 is defined by its differentiated mechanism, the evolving standard of care in its target indications, and the structure of its development partnership.

5.1 The Clinical Race for WRN Inhibition

At present, at least four distinct WRN inhibitor molecules have entered clinical trials, each with a unique profile and sponsored by different entities. The competition is fierce to be the first to establish robust clinical proof-of-concept and define a clear path to market.[1]

Table 3: Competitive Landscape of Clinical-Stage WRN Inhibitors

Drug (Synonyms)	Company	Mechanism	Clinical Phase	Key Status/Data
GSK-4418959 (IDE275)	IDEAYA / GSK	Non-covalent, Reversible, Allosteric	Phase 1/2	Preclinically active in resistant models; SYLVER trial (NCT06710847) ongoing. Initial data expected in 2025. 1
RO7589831 (VVD-214)	Vividion / Bayer	Covalent, Irreversible	Phase 1	First human data at AACR 2025: 14.3% ORR, 65.7% DCR in heavily pre-treated patients; GI toxicity noted. Roche discontinued partnership in June 2025. 1
HRO761	Novartis	Non-covalent, Allosteric	Phase 1/1b	Trial (NCT05838768) ongoing, evaluating monotherapy and combinations with ICI/irinotecan. No clinical data released to date. 1
NDI-219216	Nimbus Therapeutics	Non-covalent	Phase 1/2	Trial (NCT06898450) initiated March 2025. Preclinically claims superiority and activity against covalent resistance mutations. 1

The landscape was significantly altered in June 2025 when Roche announced its decision to terminate its partnership with Vividion (a subsidiary of Bayer) for the development of RO7589831.[44] Prior to this, RO7589831 was the clinical frontrunner, having been the first to report human data at the AACR 2025 meeting.[41] The data, from a heavily pre-treated, post-ICI population, showed a modest objective response rate of 14.3% and a disease control rate of 65.7%, accompanied by manageable but frequent low-grade gastrointestinal toxicities.[47]

Roche's exit, from a company with a formidable oncology R&D track record, suggests that the initial data for the covalent inhibitor was not deemed compelling enough to warrant continued investment. This could be due to a perceived low efficacy ceiling, concerns about the long-term tolerability of the GI side effects, or a narrow therapeutic window. This development has created a significant strategic opening for the non-covalent inhibitors. It validates the potential pitfalls of the covalent approach and elevates the importance of the differentiated mechanisms pursued by GSK/IDEAYA, Novartis, and Nimbus. The investment community and clinical investigators will now be intensely focused on the initial data from the non-covalent agents, looking for a clear improvement in both the safety profile and the efficacy signal compared to the benchmark set by RO7589831.

5.2 Current Standard of Care (SoC) and Unmet Needs in MSI-H Tumors

The therapeutic landscape for dMMR/MSI-H solid tumors has been fundamentally transformed by the advent of immune checkpoint inhibitors (ICIs), which have replaced chemotherapy as the frontline standard of care for advanced disease.

• Pembrolizumab (Keytruda): Based on the pivotal KEYNOTE-177 study, Merck's pembrolizumab received FDA approval for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer.[35] The trial demonstrated a clear superiority for pembrolizumab over standard chemotherapy, more than doubling the median progression-free survival (16.5 months vs. 8.2 months).[34] Pembrolizumab also holds a tumor-agnostic approval for any previously treated MSI-H solid tumor, making it the first therapy ever approved based on a biomarker rather than tumor location.[34]
• Dostarlimab (Jemperli): GSK's own PD-1 inhibitor, dostarlimab, is also approved for patients with dMMR recurrent or advanced solid tumors that have progressed on prior treatment.[50] More strikingly, in the neoadjuvant setting for locally advanced dMMR rectal cancer, dostarlimab has produced unprecedented results. In an ongoing study, it has achieved a 100% clinical complete response rate in all 42 patients treated, potentially allowing these patients to avoid debilitating surgery and chemoradiation.[36] This remarkable outcome led to an FDA Breakthrough Therapy Designation for this indication.[36]

Despite these transformative successes, a significant unmet medical need persists. A substantial portion of patients with MSI-H tumors—estimated to be 40-70% in some reports—either fail to respond to initial ICI therapy (primary resistance) or develop resistance after an initial period of benefit (acquired resistance).[1] For this growing population of ICI-refractory MSI-H patients, there are currently very few effective treatment options. This is the precise clinical niche that WRN inhibitors, including GSK-4418959, are initially designed to fill.

5.3 The GSK and IDEAYA Biosciences Partnership

The development of GSK-4418959 is governed by a strategic collaboration agreement established between GSK and IDEAYA in 2020, focused on multiple synthetic lethality targets.[43] The financial terms of the deal for the WRN program are particularly noteworthy and indicate a high level of conviction from GSK.

Under the agreement, GSK is responsible for 80% of the global research and development costs, a significant commitment for a large pharmaceutical partner.[19] In return for licensing the asset, IDEAYA has received and is eligible for a series of substantial payments. This includes a $7 million milestone payment for the IND acceptance and a potential $10 million payment upon the initiation of the Phase 1 dose expansion cohort.[20] Beyond these near-term payments, IDEAYA is eligible for up to $465 million in future development and regulatory milestones.[19]

The downstream economics are even more compelling for IDEAYA. Upon commercialization, the company is entitled to 50% of the net profits from U.S. sales and tiered royalties on non-U.S. net sales ranging from the high single-digits to sub-teen double-digits, in addition to up to $475 million in commercial milestones.[52] This profit-sharing and royalty structure is exceptionally favorable for a small biotech company and reflects the perceived high value and potential of the asset.

5.4 Market Opportunity and Future Outlook

The market potential for a successful WRN inhibitor is substantial. The initial target population of ICI-refractory MSI-H patients is growing as immunotherapy becomes more widely used in the frontline setting. Given the prevalence of MSI-H in major indications like endometrial (31%), colorectal (20%), and gastric (19%) cancer, this represents a significant market opportunity.[10] Success in this setting would provide a strong launchpad for expansion into earlier lines of therapy, likely through combination strategies with PD-1 inhibitors, which would dramatically increase the addressable patient population.

Looking further ahead, the field is already anticipating the emergence of resistance to WRN inhibitors themselves. Preclinical research has shown that mutations within the WRN gene can arise after prolonged exposure to inhibitors, preventing the drug from binding effectively and allowing cancer cells to survive.[53] This highlights the importance of developing next-generation inhibitors or rational combination strategies to overcome or delay resistance. The fact that GSK-4418959 is already preclinically active against models with resistance to other WRN inhibitors positions it well to address this future clinical challenge.

As of the latest available information, GSK-4418959 has not been granted any special regulatory designations, such as Orphan Drug Designation from the FDA or EMA.[24] This may be due to the total prevalence of MSI-H cancers exceeding the defined thresholds for rare diseases, or the sponsors may not have pursued this path yet. The lack of such a designation could influence the commercial exclusivity period and financial incentives for the program.

Section 6: Patent and Regulatory Information

The development and future commercialization of GSK-4418959 are protected by a robust intellectual property portfolio and guided by a clear regulatory pathway initiated with the U.S. Food and Drug Administration (FDA).

6.1 Intellectual Property

The chemical composition and therapeutic use of GSK-4418959 are covered by patent applications filed jointly by the collaborating parties. The primary patent application associated with the compound is WO2024246862 A1.[25]

• Inventors and Assignees: The list of inventors on the application includes scientists from both GSK and IDEAYA Biosciences, underscoring the collaborative nature of the discovery process. The official assignees are GlaxoSmithKline Intellectual Property (NO. 4) Ltd. and Ideaya Biosciences, Inc..[55]
• Priority and Filing: The international application claims priority from two U.S. provisional applications filed on June 1, 2023, and September 19, 2023, with the international publication date being December 5, 2024.[55]
• Scope of Claims: While the full text of the patent claims is not publicly available in the provided documentation, the nature of pharmaceutical patents and the application's description indicate the scope of protection.[56] The claims would be expected to cover the composition of matter for the specific chemical structure of GSK-4418959 and a class of related compounds. Furthermore, they would include method-of-use claims for treating cancers, with a specific focus on the patient population defined by the MSI-H and/or dMMR biomarkers.[55] The collaboration has also filed patents on other chemical scaffolds with WRN inhibitory activity, such as cyclic vinyl sulfones, demonstrating a broad intellectual property strategy to protect their position in the field.[58]

6.2 Regulatory Status

GSK-4418959 is an investigational drug currently in the early stages of clinical development.

• Investigational New Drug (IND) Clearance: In October 2024, IDEAYA Biosciences announced that the U.S. FDA had cleared the IND application for GSK-4418959. This regulatory milestone was the necessary step to permit the initiation of the first-in-human SYLVER trial in the United States.[10]
• Orphan Drug Designation (ODD): There is currently no information to suggest that GSK-4418959 has received Orphan Drug Designation from either the FDA or the European Medicines Agency (EMA).[24]
• FDA ODD: In the U.S., ODD is granted to drugs intended to treat rare diseases or conditions affecting fewer than 200,000 people. The designation provides significant incentives, including tax credits for clinical trials, exemption from user fees, and seven years of market exclusivity upon approval.[59]
• EMA ODD: In the European Union, the criteria for ODD require that the condition affects no more than 5 in 10,000 people and that the drug provides a significant benefit over existing therapies. It confers ten years of market exclusivity post-approval.[60]

The absence of an ODD for GSK-4418959 is noteworthy. It is possible that the broad indication of "MSI-H solid tumors" encompasses a patient population that exceeds the prevalence thresholds for a rare disease designation in these jurisdictions. Alternatively, the sponsors may have made a strategic decision not to apply for it at this stage. This could have implications for the drug's commercial strategy and the length of its market exclusivity period if it reaches approval.

Section 7: Safety and Tolerability Profile

As GSK-4418959 is in the earliest stages of human testing, the clinical safety profile is not yet established. The primary source of information currently comes from preclinical studies and material safety data, with the first human safety data expected from the ongoing SYLVER trial.

7.1 Preclinical Safety

The preclinical development program for GSK-4418959 provided encouraging early signals regarding its safety and therapeutic window. In in vivo studies using various xenograft models, the compound was reported to induce significant tumor growth inhibition without causing significant toxicity to the host animals.[23] This finding is crucial, as it suggests that the drug's synthetic lethal mechanism is effectively selective for cancer cells, sparing normal tissues and potentially translating to a favorable safety profile in humans. This preclinical signal is particularly important in the context of the competitive landscape, where the first-generation covalent inhibitor RO7589831 was associated with notable, albeit low-grade, gastrointestinal adverse events.[1] A cleaner preclinical toxicity profile for GSK-4418959 provides a strong rationale for its potential to be a safer, more tolerable agent in the clinic.

7.2 Material Safety Data Sheet (MSDS) Information

Material Safety Data Sheets for GSK-4418959 are available from chemical suppliers and provide information relevant to the handling of the compound in a laboratory setting.[62] These documents classify the substance as a toxic, potent pharmaceutical ingredient that can be a moderate to severe irritant to the skin and eyes, necessitating the use of standard personal protective equipment (e.g., gloves, goggles, respirator) during handling.[62] One sheet also classifies the compound as "Harmful if swallowed" (H302) and "Very toxic to aquatic life with long lasting effects" (H410) under GHS classifications.[63] It is important to note that this information pertains to the handling of the pure chemical powder and is not predictive of the safety profile of the formulated drug when administered to patients in controlled clinical doses.

7.3 Anticipated Clinical Safety Profile

As of the latest available reports, no clinical safety data for GSK-4418959 have been publicly disclosed. The SYLVER trial, which began dosing patients in late 2024, is actively collecting this information.[5] The primary endpoints for both the monotherapy dose-escalation arm (Part 1) and the combination dose-escalation arm (Part 3) are safety and the incidence of dose-limiting toxicities.[5] The initial data from these cohorts will provide the first comprehensive look at the human safety and tolerability profile of GSK-4418959.

The clinical community will be closely watching this data, particularly in comparison to the profile of the competitor covalent inhibitor, RO7589831. In its Phase 1 trial, RO7589831's most common treatment-related adverse events were gastrointestinal in nature, including nausea (52.3%), diarrhea (34.1%), and vomiting (31.8%).[47] While most events were low-grade, nausea led to dose reductions in 14% of patients, indicating a potential tolerability issue that could limit its utility.[41] The demonstration of a superior safety profile, particularly with respect to GI toxicity, would represent a major clinical and commercial advantage for GSK-4418959 and its non-covalent mechanism.

Section 8: Conclusion and Strategic Recommendations

GSK-4418959 (IDE275) is emerging as a highly promising and strategically positioned asset in the novel therapeutic class of WRN inhibitors. It represents a potential paradigm shift for the treatment of MSI-H solid tumors, a field currently dominated by immunotherapy but with a clear and growing unmet need for patients with refractory disease. The drug's development is built upon a strong foundation of a validated synthetic lethal mechanism, a differentiated molecular profile, robust preclinical data, and the powerful backing of a major pharmaceutical and biotechnology partnership.

The drug's key strength lies in its differentiated, non-covalent, reversible mechanism of action. This was a deliberate and insightful design choice that appears to confer a critical advantage: the ability to overcome acquired resistance to first-generation covalent inhibitors. This preclinical finding, if translated to the clinic, could firmly establish GSK-4418959 as a best-in-class agent. Furthermore, the SYLVER clinical trial is intelligently designed to provide the fastest possible path to demonstrating clinical value by focusing on the well-defined and underserved population of MSI-H patients whose tumors have progressed after immunotherapy.

The competitive landscape, while active, has been favorably reshaped by the recent discontinuation of the front-running covalent inhibitor, RO7589831. This event has simultaneously cleared a major competitor and raised the stakes for the remaining non-covalent agents, placing GSK-4418959 in a prime position to lead the field. However, the program is not without challenges. The efficacy bar set by immunotherapies in the frontline setting is exceptionally high, and the clinical translation of preclinical promise is never guaranteed.

Based on this comprehensive analysis, the following strategic outlook and recommendations are proposed:

• For Investors and Industry Analysts: The most critical near-term catalyst for GSK-4418959 is the initial data release from the SYLVER (NCT06710847) trial. Close attention should be paid to two key aspects:

1. Safety and Tolerability (from Parts 1 and 3): The safety profile will be paramount. A key metric for success will be a significantly lower rate of grade 2 or higher gastrointestinal adverse events compared to the profile of RO7589831. A clean safety profile would strongly support its best-in-class potential.
2. Preliminary Efficacy (from Part 2): The Objective Response Rate (ORR) in the ICI-refractory colorectal and endometrial cancer cohorts will be the primary measure of activity. An ORR that is meaningfully superior to the 14.3% benchmark set by RO7589831 in a similar population would be a major validation of the drug's potential and a significant positive inflection point for the program.

• For Clinicians and Researchers: The scientific community should monitor for presentations at major oncology conferences (e.g., AACR, ASCO, ESMO) for the first clinical data. Beyond the primary efficacy and safety endpoints, data on pharmacodynamic biomarkers—such as the induction of γH2AX in tumor biopsies and the results of the target occupancy assay—will be crucial for confirming that the drug is behaving in patients as predicted by the preclinical models. Emerging data on potential mechanisms of resistance from this and other WRN inhibitor trials will also be vital for planning future research and combination strategies.
• For the Development Strategy: The current strategy of prioritizing the monotherapy dose-expansion in the post-ICI setting (Part 2) and the combination dose-escalation (Part 3) is sound. Rapidly generating proof-of-concept in the ICI-refractory population represents the path of least resistance to an initial regulatory approval. Success in this setting would provide a strong foundation to then challenge the standard of care in earlier lines of therapy with the PD-1 inhibitor combination, which holds the greatest long-term commercial potential. The continued development of refined patient selection biomarkers, such as quantifying TA-repeat load, could further enhance the probability of success in future, larger trials.

Works cited

1. Drugging WRN: Clinical Proof-of-Concept Established - AACR Journals, accessed June 20, 2025, https://aacrjournals.org/cdnews/news/2332/Drugging-WRN-Clinical-Proof-of-Concept-Established
2. AACR Chicago 2025: New Drugs on the Horizon - Drug Hunter, accessed June 20, 2025, https://drughunter.com/articles/aacr-chicago-2025-new-drugs-on-the-horizon
3. Abstract ND10: An innovative and reversible WRN helicase inhibitor, GSK4418959 (IDE275), emerges as a promising clinical candidate for MSI-H cancers - AACR Journals, accessed June 20, 2025, https://aacrjournals.org/cancerres/article/85/8_Supplement_2/ND10/762490/Abstract-ND10-An-innovative-and-reversible-WRN
4. A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors (SYLVER) - ClinicalTrials.Veeva, accessed June 20, 2025, https://ctv.veeva.com/study/a-study-to-investigate-the-safety-pharmacokinetics-and-preliminary-effectiveness-of-gsk4418959-alo
5. Abstract CT194: First-in-human, phase 1/2 study of GSK4418959, an ..., accessed June 20, 2025, https://aacrjournals.org/cancerres/article/85/8_Supplement_2/CT194/761387/Abstract-CT194-First-in-human-phase-1-2-study-of
6. WRN as a Novel Target of Synthetic Lethality: Current Advances and Future Perspectives | Journal of Medicinal Chemistry - ACS Publications, accessed June 20, 2025, https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01114
7. WRN Inhibition Leads to its Chromatin-Associated Degradation Via ..., accessed June 20, 2025, https://www.biorxiv.org/content/10.1101/2023.12.08.570895v1.full-text
8. Clinical prospects of WRN inhibition as a treatment for MSI tumours - ResearchGate, accessed June 20, 2025, https://www.researchgate.net/publication/365434079_Clinical_prospects_of_WRN_inhibition_as_a_treatment_for_MSI_tumours
9. Exonucleases - Drugs, Indications, Patents - Patsnap Synapse, accessed June 20, 2025, https://synapse.patsnap.com/target/c8047563bbfe476ebd3ae1b12c7e5797
10. IDEAYA's WRN Inhibitor IDE275 Shows Promise for MSI-H Cancers, Featured in AACR 2025 Oral Presentation - MedPath, accessed June 20, 2025, https://trial.medpath.com/news/f7304895d6b23554/ideaya-s-wrn-inhibitor-ide275-shows-promise-for-msi-h-cancers-featured-in-aacr-2025-oral-presentation
11. Interest builds in a new synthetic lethality story | ApexOnco - Oncology Pipeline, accessed June 20, 2025, https://www.oncologypipeline.com/apexonco/interest-builds-new-synthetic-lethality-story
12. Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells - PMC, accessed June 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6435321/
13. Colorectal Cancers and Microsatellite Instability - TURKISH JOURNAL OF ONCOLOGY, accessed June 20, 2025, https://onkder.org/pdf.php?&id=1487
14. The WRN helicase: resolving a new target in microsatellite unstable cancers, accessed June 20, 2025, https://www.researchgate.net/publication/353320383_The_WRN_helicase_resolving_a_new_target_in_microsatellite_unstable_cancers
15. Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells | eLife, accessed June 20, 2025, https://elifesciences.org/articles/43333
16. Abstract PR007: Discovery of HRO761, a novel, first-in-class clinical stage WRN inhibitor with potent and selective anti-tumor activity in cancers with microsatellite instability - ResearchGate, accessed June 20, 2025, https://www.researchgate.net/publication/376160812_Abstract_PR007_Discovery_of_HRO761_a_novel_first-in-class_clinical_stage_WRN_inhibitor_with_potent_and_selective_anti-tumor_activity_in_cancers_with_microsatellite_instability
17. Abstract 5750: Discovery of GSK4418959 (IDE275): A novel, non ..., accessed June 20, 2025, https://aacrjournals.org/cancerres/article/85/8_Supplement_1/5750/757884/Abstract-5750-Discovery-of-GSK4418959-IDE275-A
18. IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor | Morningstar, accessed June 20, 2025, https://www.morningstar.com/news/pr-newswire/20250326sf50078/ideaya-announces-oral-presentation-at-the-new-drugs-on-the-horizon-series-at-aacr-2025-for-ide275-gsk959-a-phase-1-werner-helicase-inhibitor
19. GSK-4418959 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 20, 2025, https://synapse.patsnap.com/drug/b9297958361a4ab89050803d1619b685
20. IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors, accessed June 20, 2025, https://ir.ideayabio.com/2024-10-28-IDEAYA-Biosciences-Announces-IND-Clearance-for-Werner-Helicase-Development-Candidate-IDE275-GSK959-for-a-Phase-1-Study-in-MSI-High-Solid-Tumors
21. Abstract 6393: Patient selection, target engagement and ..., accessed June 20, 2025, https://aacrjournals.org/cancerres/article/85/8_Supplement_1/6393/760253/Abstract-6393-Patient-selection-target-engagement
22. IDE275 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed June 20, 2025, https://synapse.patsnap.com/drug/44de62155f214a808e68cda3185c8476
23. GSK4418959 | CAS#3064599-36-3 | WRN inhibitor - MedKoo Biosciences, accessed June 20, 2025, https://www.medkoo.com/products/61642
24. GSK 4418959 - AdisInsight - Springer, accessed June 20, 2025, https://adisinsight.springer.com/drugs/800080562
25. GSK4418959 (IDE275) | WRN inhibitor | Probechem Biochemicals, accessed June 20, 2025, https://www.probechem.com/products_GSK4418959.html
26. Helicase inhib News - LARVOL Sigma, accessed June 20, 2025, https://sigma.larvol.com/moa.php?MoaId=875631&tab=newstrac
27. profiles - Drug Hunter, accessed June 20, 2025, https://drughunter.com/category/profiles
28. Nimbus Therapeutics Initiates First-in-Human Trial of NDI-219216 for MSI-H Tumors Resistant to Standard Therapies - MedPath, accessed June 20, 2025, https://trial.medpath.com/news/7db1d21d9342af9b/nimbus-therapeutics-initiates-first-in-human-trial-of-ndi-219216-for-msi-h-tumors-resistant-to-standard-therapies
29. New Drugs on the Horizon sessions provide first look at 12 new therapeutics, accessed June 20, 2025, https://www.aacrmeetingnews.org/news/new-drugs-on-the-horizon-sessions-provide-first-look-at-12-new-therapeutics/
30. A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors - CenterWatch, accessed June 20, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06710847/a-study-to-investigate-the-safety-pharmacokinetics-and-preliminary-effectiveness-of-gsk4418959-alone-or-in-combination-with-other-anti-cancer-agents-in-participants-with-solid-tumors
31. A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors - PAN Foundation Trial Finder, accessed June 20, 2025, https://trialfinder.panfoundation.org/en-US/trial/listing/560442
32. A Phase 1/2 First-Time-in-Human open-label multicenter dose escalation and expansion study of the oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors (SYLVER) - Clinical Trials, accessed June 20, 2025, https://clinicaltrials.med.nyu.edu/clinicaltrial/2607/phase-12-first-time-in-human-open-label/
33. Abstract CT194: First-in-human, phase 1/2 study of GSK4418959, an oral Werner DNA helicase inhibitor, alone or combined with other anticancer agents in adults with advanced mismatch repair-deficient or microsatellite instability-high solid tumors (SYLVER) - ResearchGate, accessed June 20, 2025, https://www.researchgate.net/publication/391167218_Abstract_CT194_First-in-human_phase_12_study_of_GSK4418959_an_oral_Werner_DNA_helicase_inhibitor_alone_or_combined_with_other_anticancer_agents_in_adults_with_advanced_mismatch_repair-deficient_or_mic?_tp=eyJjb250ZXh0Ijp7InBhZ2UiOiJzY2llbnRpZmljQ29udHJpYnV0aW9ucyIsInByZXZpb3VzUGFnZSI6bnVsbCwic3ViUGFnZSI6bnVsbH19
34. Merck's KEYTRUDA® (pembrolizumab) Superior to Standard of ..., accessed June 20, 2025, https://www.merck.com/news/mercks-keytruda-pembrolizumab-superior-to-standard-of-care-chemotherapy-in-patients-with-msi-h-colorectal-cancer/
35. FDA approves pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer, accessed June 20, 2025, https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-first-line-treatment-msi-hdmmr-colorectal-cancer
36. Jemperli (dostarlimab) receives US FDA Breakthrough Therapy ..., accessed June 20, 2025, https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-receives-us-fda-breakthrough-therapy-designation-for-locally-advanced-dmmrmsi-h-rectal-cancer/
37. Neoadjuvant Dostarlimab Eradicates Disease in 82% of Mismatch Repair–Deficient Solid Tumors - OncLive, accessed June 20, 2025, https://www.onclive.com/view/neoadjuvant-dostarlimab-eradicates-disease-in-82-of-mismatch-repair-deficient-solid-tumors
38. Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells, accessed June 20, 2025, https://iris.unito.it/bitstream/2318/2064852/1/cd-24-0052.pdf
39. Research advances in immunotherapy combined with DNA damage response inhibitors for liver cancer therapy - OAE Publishing Inc., accessed June 20, 2025, https://www.oaepublish.com/articles/2394-4722.2023.175
40. Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application - Frontiers, accessed June 20, 2025, https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.661115/pdf
41. AACR 2025 – Roche sets a bar in Werner helicase inhibition - Oncology Pipeline, accessed June 20, 2025, https://www.oncologypipeline.com/apexonco/aacr-2025-roche-sets-bar-werner-helicase-inhibition
42. Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | Novartis, accessed June 20, 2025, https://www.novartis.com/clinicaltrials/study/nct05838768
43. Another pan-KRAS project enters the clinic | ApexOnco - Oncology Pipeline, accessed June 20, 2025, https://www.oncologypipeline.com/apexonco/another-pan-kras-project-enters-clinic
44. Werner not good enough for Roche | ApexOnco - Clinical Trials news and analysis, accessed June 20, 2025, https://www.oncologypipeline.com/apexonco/werner-not-good-enough-roche
45. Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers - PubMed, accessed June 20, 2025, https://pubmed.ncbi.nlm.nih.gov/38658754/
46. AACR: First-in-class covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial, accessed June 20, 2025, https://www.mdanderson.org/newsroom/aacr-first-in-class-covalent-werner-helicase-inhibitor-shows-clinical-proof-of-concept-in-phase-I-trial.h00-159775656.html
47. Abstract CT016: First-in-human (FIH) phase 1 trial of the oral first-in-class covalent Werner helicase (WRN) inhibitor RO7589831 in patients with microsatellite instable (MSI) and/or mismatch repair deficient (dMMR) advanced solid tumors | Cancer Research - AACR Journals, accessed June 20, 2025, https://aacrjournals.org/cancerres/article/85/8_Supplement_2/CT016/761432/Abstract-CT016-First-in-human-FIH-phase-1-trial-of
48. FDA Approval Summary: Pembrolizumab for the first-line treatment of patients with MSI-H/dMMR advanced unresectable or metastatic colorectal carcinoma, accessed June 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8416693/
49. FDA Approves Merck's KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer, accessed June 20, 2025, https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-for-adult-and-pediatric-patients-with-unresectable-or-metastatic-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-cance/
50. FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer, accessed June 20, 2025, https://www.targetedonc.com/view/fda-grants-dostarlimab-breakthrough-therapy-designation-in-dmmr-msi-h-rectal-cancer
51. Jemperli (dostarlimab-gxly) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer | GSK US, accessed June 20, 2025, https://us.gsk.com/en-us/media/press-releases/jemperli-dostarlimab-gxly-receives-us-fda-breakthrough-therapy-designation-for-locally-advanced-dmmrmsi-h-rectal-cancer/
52. IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor - PR Newswire, accessed June 20, 2025, https://www.prnewswire.com/news-releases/ideaya-announces-oral-presentation-at-the-new-drugs-on-the-horizon-series-at-aacr-2025-for-ide275-gsk959-a-phase-1-werner-helicase-inhibitor-302411575.html
53. Key mutations discovered in cancer cells linked to WRN inhibitor resistance, accessed June 20, 2025, https://www.news-medical.net/news/20241024/Key-mutations-discovered-in-cancer-cells-linked-to-WRN-inhibitor-resistance.aspx
54. EMA Says Yes To GSK's Omjjara, UCB's Rystiggo and Novartis' Spexotras, accessed June 20, 2025, https://insights.citeline.com/PS149335/EMA-Says-Yes-To-GSKs-Omjjara-UCBs-Rystiggo-and-Novartis-Spexotras/
55. Synthetic Lethality as Emerging Treatment for Cancer: An Example by Using the Werner Syndrome Helicase (WRN) Inhibitors | ACS Medicinal Chemistry Letters - ACS Publications, accessed June 20, 2025, https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00272
56. accessed January 1, 1970, https://worldwide.espacenet.com/patent/search/family/088336933/publication/WO2024246862A1?q=WO2024246862
57. accessed January 1, 1970, https://worldwide.espacenet.com/publicationDetails/biblio?II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20241205&CC=WO&NR=2024246862A1
58. WO2023062575A1 - Cyclic vinyl sulfone compounds as wrn inhibitors - Google Patents, accessed June 20, 2025, https://patents.google.com/patent/WO2023062575A1/en
59. Designating an Orphan Product: Drugs and Biological Products - FDA, accessed June 20, 2025, https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products
60. European Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemia - AB Science, accessed June 20, 2025, https://www.ab-science.com/european-medicines-agency-has-granted-orphan-drug-designation-in-the-european-union-for-ab8939-in-the-treatment-of-acute-myeloid-leukemia/
61. Orphan designation: Overview | European Medicines Agency (EMA), accessed June 20, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/orphan-designation-overview
62. GSK4418959 | Safety Data Sheet - Selleck Chemicals, accessed June 20, 2025, https://www.selleckchem.com/msds/MSDS_E6402.pdf
63. Safe Data Sheet - DC Chemicals, accessed June 20, 2025, https://www.dcchemicals.com/msds/MSDS_DC60857.html
64. IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update, accessed June 20, 2025, https://media.ideayabio.com/2025-05-06-IDEAYA-Biosciences,-Inc-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Update